PAOLA-1 (2023 Update): Final Overall Survival Results — Olaparib plus Bevacizumab First-Line Maintenance in Ovarian Cancer
Olaparib combined with bevacizumab provided a OS benefit for HRD-positive ovarian cancer patients.
Ovarian Cancer
HIPEC in ovarian cancer
Korean HIPEC Trial: HIPEC After Primary or Interval Cytoreductive Surgery in Ovarian Cancer
The addition of HIPEC after interval cytoreductive surgery following neoadjuvant chemotherapy provided significant improvements in PFS and OS.
Mucinous Ovarian Carcinoma
mEOC/GOG-0241: Oxaliplatin-Capecitabine vs. Carboplatin-Paclitaxel in Mucinous Epithelial Ovarian Cancer
Neither oxaliplatin-capecitabine nor bevacizumab significantly improved OS or PFS compared to paclitaxel-carboplatin in advanced-stage mucinous ovarian cancer.
Germ Cell Tumors of the Ovary
Granulosa Cell Tumors
Secondary Debulking Mini-Tutorial
Low-Grade Serous Ovarian Carcinoma
Relevant Study Summaries
GOG 281: Trametinib in recurrent low-grade
MILO/ENGOT-ov11: Binimetinib in Recurrent Low-Grade Serous
In low-grade serous ovarian cancer, Binimetinib did not significantly improve PFS compared to standard of care chemotherapy.